Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Contemp Clin Trials. 2016 May;48:146-52. doi: 10.1016/j.cct.2016.03.009. Epub 2016 Apr 16.

Examining the efficacy of d-cycloserine to augment therapeutic learning in depression.

Author information

1
Department of Psychological and Brain Sciences, Boston University, United States. Electronic address: mwotto@bu.edu.
2
Department of Psychological and Brain Sciences, Boston University, United States.
3
Institute for Mental Health Research and Department of Psychology, University of Texas at Austin, United States.
4
Department of Psychology, Southern Methodist University, United States.
5
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, United States.
6
Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, United States.

Abstract

Despite advances in individual and combined treatments for major depression, issues with non-response and partial-response remain relatively common, motivating the search for new treatment strategies. This study aims to develop one such novel treatment. In this proof-of-concept study, we are investigating whether the treatment enhancing effects of d-cycloserine (DCS) administration can be extended outside the extinction-learning paradigms where they have been primarily examined. Using uniform delivery of cognitive behavioral therapy (CBT) content via computer-administered interventions for depression, we are assessing the value of pre-session administrations of DCS for retention of therapeutic learning. Recall of this information is evaluated in conjunction with performance on standardized tests of memory recall with both emotional and non-emotional stimuli. Specifically, in a randomized, double-blind trial we will compare the benefits of two pre-session administrations of DCS augmentation to those achieved by similar administrations of modafinil or placebo. Because modafinil is associated with a number of discriminable effects in addition to cognitive enhancement (e.g., feelings of vigor, alertness, positive mood); whereas these effects would not be expected with DCS, we will assess drug context effects in relation to memory augmentation effects.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02376257.

KEYWORDS:

Cognitive behavioral therapy; Declarative memory; Depression; Modafinil; d-cycloserine

PMID:
27094721
DOI:
10.1016/j.cct.2016.03.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center